Waters and NIBRT form partnership
Waters (Milford, Massachusetts, USA) has announced that it has formed a partnership with the Irish National Institute for Bioprocessing Research and Training (NIBRT) to address the world?s most challenging diseases through training and research.
Waters (Milford, Massachusetts, USA) has announced that it has formed a partnership with the Irish National Institute for Bioprocessing Research and Training (NIBRT) to address the world’s most challenging diseases through training and research.
Together Waters and NIBRT have established the Complete Product and Processing Characterization Facility (CPPCF) that will provide laboratory-based scientific training and retraining of ‘fit-for-purpose’ biopharmaceutical analysis. The facility will also educate scientists on current and future US and European drug regulations.
The partnership also establishes NIBRT as a Waters Centre of Innovation in the area of glycobiology research.
Mr Sean Sherlock TD, Minister for Research and Innovation, Department of Jobs, Enterprise and Innovation, said, “The combination of Pauline Rudd's [NIBRT’s principal investigator] expertise in glycan analysis and Waters technology for analysis of complex biological samples provides a unique combination of capabilities that can help underpin Ireland's continued reputation as a centre of excellence for the very highest quality standards in biopharmaceutical manufacturing. I'm truly delighted to announce this collaboration as it will surely assist both NIBRT and Waters in further cementing their reputation as providers of choice for the biopharmaceutical industry and Ireland's reputation as a world leading location for biotech manufacturing.”
NIBRT's interim director, Professor Ian Marison, commented, “This partnership will enable NIBRT, with the help of Waters, to provide advanced solutions for the pharmaceutical industry, including protein characterization, N- and O- glycan analysis.”
For more information please visit ref="http://www.waters.com">www.waters.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
